EORTC and Medidata Extend Partnership to Enhance Oncology Clinical Trials
核心洞察
The European Organisation for Research and Treatment of Cancer (搜索) (EORTC) has extended its partnership with Medidata for four years.
The collaboration aims to improve patient access to oncology clinical trials and accelerate the delivery of new treatments.
EORTC is leveraging 13 Medidata solutions to streamline data management and enhance patient engagement in clinical trials.
Medidata, a Dassault Systèmes brand, and the European Organisation for Research and Treatment of Cancer (搜索) (EORTC) have announced a four-year extension of their partnership, aiming to transform oncology clinical trials. This collaboration seeks to broaden patient access, simplify participation, and expedite the availability of novel cancer treatments.
Streamlining Clinical Trial Management
EORTC is now utilizing 13 Medidata solutions, which allows researchers to access and manage all clinical data in a centralized location, thereby improving the overall trial experience for patients. According to Vassilis Golfinopoulos, headquarters director at EORTC, the decision to expand the Medidata Platform was based on years of successful collaboration and a shared vision for innovative clinical trial data management.
Enhanced Patient Experience and Data Quality
The extended partnership focuses on improving the clinical trial experience for patients through mobile device engagement and enabling researchers to make quicker, more informed decisions. Janet Butler, executive vice president, head of global sales at Medidata, emphasized that the integration of solutions like Medidata Rave CTMS and Medidata Rave eTMF will provide EORTC researchers with higher quality data. This enhancement is expected to shorten study timelines and improve the safety of oncology trials.
Exploring AI-Driven Cancer Care
Furthermore, the collaboration will explore joint research and data initiatives using Medidata AI solutions, with the goal of establishing improved standards of cancer (搜索) care. This forward-looking approach aims to leverage advanced technologies to refine treatment strategies and patient outcomes in oncology.